United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company delivered huge revenue and earnings growth that beat Wall Street's expectations.

Pfizer Knocks It Out of the Park With Its Q1 Results

Pfizer Inc. (NYSE:PFE) said it expects to make US$26bn (£19bn) revenues from the COVID-19 vaccine developed with BioNTech this year. The pharma giant upgraded full-year guidance to US$70.5-72.5bn to include better than expected contributions for the jab, which will partially be offset by R&D expenses.

Pfizer expects to make US$26bn annual revenues from COVID-19 vaccine

The shares of Pfizer Inc. (NYSE:PFE) are down 0.8% at $39.62 at last check, despite the drug maker reporting first-quarter earnings and revenue that beat Wall Street's forecasts.

Option Traders Blast PFE After Earnings, Revenue Beat

Pfizer has sold hundreds of millions of doses of its COVID-19 vaccine to the United States, and even more around the globe, resulting in more than $3.5 billion in revenue during the first three months of 2021, the company said Tuesday.  Sales of the two-shot vaccine made up nearly a quarter of the pharmaceutical giant's first-quarter revenues of $14.6 billion, easily its biggest income driver, though the company has been tight-lipped about how those sales translate to profits.

Pfizer brought in $3.5 billion from COVID-19 vaccine sales in the first 3 months of 2021 (PFE)

Shares of Pfizer rose on Tuesday after the drugmaker raised forecasts for 2021 on the expectation of stronger full-year earnings than previously expected. The New York-based drugmaker said it now expects COVID-19 vaccine revenues of around $26 billion, 73% higher than the $15 billion initial target, and now sees adjusted earnings per share of $3.55-$3.65, up from $3.10-$3.20, according to a statement Tuesday.

Pfizer climbs after boosting its 2021 COVID-19 vaccine sales forecast by 73%

BioNTech SE

Full FDA approval would allow the vaccine to be administered after the Covid-19 pandemic ends.

Pfizer Will File For Full FDA Approval For Covid-19 Vaccine By End Of May

Pfizer (PFE) delivered earnings and revenue surprises of 17.72% and 8.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Q1 Earnings and Revenues Surpass Estimates

Pfizer Inc. (NYSE: PFE) reported its financial results for the fiscal first quarter on Tuesday that topped analysts' estimates for earnings and revenue. On the back of hawkish quarterly performance, the company also raised its guidance for the full year.

4 key takeaways from Pfizer's Q1 earnings report

Pfizer's (PFE) Q1 earnings and revenue exceeded analysts' expectations, while COVID-19 vaccine revenue far surpassed estimates.

Pfizer Q1 2021 Earnings Report Recap

Pfizer Inc. significantly increased revenue projections from its Covid-19 vaccine for the year, as sales from the shot over the first three months of 2021 lifted the company to a stronger quarterly profit.

Pfizer's COVID-19 vaccine lifts quarterly results

Pfizer Inc (NYSE: PFE) reported Q1 sales of $14.6 billion up 45% Y/Y, beating a consensus of $13.6 billion. It saw a 3% favorable impact of foreign exchange.

Pfizer Beats Q1 Wall Street Estimates; Sees COVID-19 Vaccine Sales Of $26B In FY21

LONDON--(BUSINESS WIRE)--ViiV Healthcare announces the initiation of a rolling submission of a new drug application with the US FDA for cabotegravir for the prevention of HIV.

ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

Shares of Pfizer Inc. jumped 1.6% toward a near five-month high in premarket trading Tuesday, after the drug giant beat earnings expectations and raised its full-year outlook, as revenue expectations for its COVID-19 vaccine jumped 73%. Net income rose to $4.88 billion, or 86 cents a share, from $3.36 billion, or 60 cents a share, in the year-ago period.

Pfizer beats earnings expectations and lifts guidance, as COVID-19 revenue outlook increases 73%

Pfizer Inc on Tuesday raised its annual sales forecast for the COVID-19 vaccine it co-developed with Germany's BioNTech SE, as a vaccination drive across the globe intensifies.

Pfizer lifts annual sales forecast for COVID-19 vaccine

In its earnings report, Pfizer said first-quarter sales of its Covid-19 vaccine was $3.5 billion.

Pfizer reports $3.5 billion in quarterly sales from Covid vaccine, raises outlook

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2021 and raised 2021 guidance(3) for revenues and Adjusted diluted EPS(2) driven by the updated expectations for contributions to 2021 performance from BNT162b2, the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, as well as the strong performance of the business excluding BNT162b2, partially offset by anticipated additional R&D investments into vaccines to protect against COVID-19, as well as ot

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

Cummins

CVS Health

Mosaic

T-Mobile US

Some of the stocks that may grab investor focus today are: Wall Street expects CVS Health Corp (NYSE: CVS) to report quarterly earnings at $1.71 per share on revenue of $68.39 billion before the opening bell. CVS shares rose 2.5% to $79.66 in after-hours trading.

5 Stocks To Watch For May 4, 2021

The Food and Drug Administration has plans to authorize the emergency use of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) jointly-developed COVID-19 vaccine in adolescents aged between 12 to 15 years, the New York Times reported Monday. What Happened: The move means that the campaign to vaccinate against COVID-19 will potentially expand to millions more, as per the Times.

Pfizer COVID-19 Vaccine Expected To Get FDA Emergency Approval For Age Group 12-15 Next Week

Pfizer Inc. PFE is expected to get Food and Drug Administration approval for use of its COVID-19 vaccine in children aged 12 to 15, according to a report late Monday. Unnamed federal officials told The New York Times that the approval could come as early as late this week.

Pfizer COVID-19 vaccine to be approved for 12- to 15-year olds: report

The Food and Drug Administration is set to authorize the use of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 12-15 years old as early as next week, The New York Times reported Monday. Following FDA authorization, an advisory panel from the Centers for Disease Control and Prevention will review data and results from clinical trials to draft recommendations on the use of the vaccine for those 12-15 years old, according to The Times report.

FDA to authorize the use of the Pfizer COVID-19 vaccine for those ages 12-15 as early as next week, The New York Times reports

Amazon

Novavax

Berkshire Hathaway, Pfizer, Novavax and Amazon were our top stock trades for Tuesday. Now, let's get a look at the charts as we kickoff May.

4 Top Stock Trades for Tuesday: Berkshire, PFE, NVAX, AMZN

We expect Pfizer to likely post revenue and earnings above the consensus estimates, primarily led by its Covid-19 vaccine.

All Eyes On Covid-19 Vaccine Contribution As Pfizer Reports Its Q1

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.

Pfizer's (PFE) Key Drugs Likely to Drive Its Q1 Earnings

AstraZeneca

Johnson & Johnson

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

Shares of Pfizer Inc. gained 2.2% in trading on Monday after the pharmaceutical company said it will donate $70 million in medicine to India, which is facing the worst surge in COVID-19 cases worldwide during the pandemic. The drugmaker also reiterated that the COVID-19 vaccine it developed with BioNTech SE has not yet been approved in India, though the application was "submitted months ago.

News for Pfizer Stock (PFE)